Keywords: AstraZeneca, David Brennan, Ex-CEO, Remuneration, Bonus, Share wards

Ex-AstraZeneca CEO David Brennan to forego bonus

Article | 17 July 2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed yesterday the remuneration arrangements relating to David Brennan’s abrupt resignation as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

AstraZeneca

Go to company listing